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Influenza peptide antigens coding for conserved T cell epitopes have the capacity to 
induce cross-protective influenza-specific immunity. Short peptide antigens used as a 
vaccine, however, often show poor immunogenicity. In this study, we demonstrate that 
whole-inactivated influenza virus (WIV) acts as an adjuvant for influenza peptide antigens, 
as shown by the induction of peptide-specific CD8+ T cells in HLA-A2.1 transgenic mice 
upon vaccination with the influenza-M1-derived GILGFVFTL peptide (GIL), formulated 
with WIV. By screening various concentrations of GIL and WIV, we found that both 
components contributed to the GIL-specific T cell response. Whereas co-localization 
of the peptide antigen and WIV adjuvant was found to be important, neither physical 
association between peptide and WIV nor fusogenic activity of WIV were relevant for the 
adjuvant effect of WIV. We furthermore show that WIV may adjuvate T cell responses 
to a variety of peptides, using pools of either conserved wild-type influenza peptides or 
chemically altered peptide ligands. This study shows the potential of WIV as an adjuvant 
for influenza peptides. The simple formulation process and the solid safety record of 
WIV make this an attractive adjuvant for T  cell peptides, and may also be used for 
non-influenza antigens.
Keywords: whole-inactivated influenza virus, adjuvant, T cell peptide, cTl, design of experiments, formulation, 
peptide vaccine
inTrODUcTiOn
Current seasonal influenza vaccines exert their protective effect mainly through the induction of 
virus-specific neutralizing antibodies directed against the surface proteins of influenza virus (1). 
However, changes in the influenza virus surface proteins caused by antigenic drift or shift allow 
influenza viruses to evade these antibodies. Therefore, influenza vaccines require regular updates 
Abbreviations: WIV, whole-inactivated influenza virus; CTLs, cytotoxic CD8+ T cells; APCs, antigen-presenting cells; PAMPs, 
pathogen-associated molecular patterns; IFA, incomplete Freund’s adjuvant; CPLs, chemically altered peptide ligands; DCs, 
dendritic cells; GIL, GILGFVFTL (M158–66) peptide; FMY, FMYSDFHFI (PA46–54) peptide; NML, NMLSTVLGV (PB1413–421) 
peptide; SFU, spot-forming units.
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or need to be completely renewed, to be able to protect against 
circulating influenza viruses.
By contrast, cellular immune components such as CD8+ and 
CD4+ T  cells often recognize conserved epitopes of internal 
influenza virus proteins. This allows these T cells to cross-react 
with various influenza strains or even subtypes, and provides 
the host with a better protection against drifting or shifting 
influenza virus strains (2–4). Cytotoxic CD8+ T  cells (CTLs) 
can clear virus-infected host cells, thereby controlling influenza 
virus infections by inhibiting viral replication and potentially 
limiting viral spread. The induction of influenza virus-specific 
T  cells in addition to neutralizing antibodies may, therefore, 
increase the effectiveness of influenza vaccines. Currently, mul-
tiple approaches for the induction of influenza-specific T  cell 
responses by vaccination are being investigated (5, 6).
Short linear peptides that represent conserved T cell epitopes 
can be used as antigens to induce influenza virus-specific CTLs 
(6). However, peptides are generally not that immunogenic, as 
they are inefficiently delivered to antigen-presenting cells (APCs), 
lack pathogen-associated molecular patterns (PAMPs) to trigger 
the immune system, and are rapidly degraded. Inefficient delivery 
of an antigenic peptide and lack of PAMPs can be overcome by 
formulation of the peptide with an appropriate adjuvant (7).
Water-in-oil emulsions such as incomplete Freund’s adjuvant 
(IFA) are effective adjuvants for peptides, but are associated with 
substantial adverse events such as lesion formation at the site of 
injection, making them undesirable for use in humans for vac-
cination (6). Thus, alternative adjuvants for peptide antigens are 
highly sought after.
Whole-inactivated influenza virus (WIV) possesses an innate 
adjuvant capability in the form of viral single-stranded RNA 
(ssRNA), which is a potent TLR7 agonist (8). Furthermore, WIV 
contains CD4+ epitopes, which are favorable for the induction 
of functional CD8+ T cell and B cell responses (9). WIV is also 
more reactogenic than split and subunit influenza vaccines, 
which could be linked to its increased immunogenicity. A recent 
study by Babb et al. described that gamma-irradiated WIV can 
act as an adjuvant for a Semliki Forest virus (SFV) vaccine, which 
significantly increased the induction of SFV-specific antibodies in 
mice (10). However, it has not been studied whether WIV can be 
used as an adjuvant for T cell-inducing peptide-based vaccines.
Another method to increase the immunogenicity of peptides 
is to increase their binding affinity to MHC class I molecules 
by chemical modification. These so-called, chemically altered 
peptide ligands (CPLs) derived from HLA-A2.1-restricted 
epitopes were shown to possess a higher affinity to HLA-A2.1, 
and induced more IFN-γ positive splenocytes compared to wild-
type (WT) epitopes in HLA-A2.1 transgenic mice (11). Chemical 
modification of subdominant peptide epitopes might, therefore, 
increase the breadth of peptide-specific T cell responses.
In the current study, first we investigated the effect of the addi-
tion of WIV to the GILGFVFTL (GIL, M158–66) peptide, which 
is the dominant CD8+ T  cell epitope in HLA-A2.1-restricted 
individuals. Next, we performed a dose-finding study to deter-
mine the optimal WIV and peptide antigen concentrations for 
the induction of peptide-specific T cells. Furthermore, we studied 
the effect of WIV-peptide co-localization, association, and WIV 
membrane fusion activity on the adjuvant activity of WIV. Finally, 
we investigated the adjuvant activity of WIV on influenza pep-
tides coding for conserved WT T cell epitopes and CPL variants.
MaTerials anD MeThODs
Formulation of Vaccines
Influenza A/PR/8/34 (H1N1) virus was propagated on fertilized 
eggs and inactivated with β-propiolactone as described before 
(12, 13), which yielded PR8 WIV bulk vaccine. For certain 
experiments, WIV was subsequently fusion-inactivated by lower-
ing the buffer pH to 4.5 for 15 min at 37°C with a pre-titrated 
volume of 1 M HCl (Sigma-Aldrich) and was then brought back 
to physiological pH by dialyzing overnight against PBS pH 7.2 
(Life Technologies). Membrane fusion capacity was subsequently 
determined by a hemolysis assay as described previously (14).
The Netherlands Cancer Institute kindly provided the 
HLA-A2.1-restricted influenza GILGFVFTL (GIL, M158–66), 
FMYSDFHFI (FMY, PA46–54), and NMLSTVLGV (NML, PB1413–421) 
peptides, and chemically altered CPLs [am-phg]ILGFVFTL (G1), 
[4-FPHE]MYSDFHF[2-AOC] (F5), and N[NLE]LSTVLGV 
(N53), as published by Rosendahl Huber et al. (11) (Figure S1 in 
Supplementary Material).
Influenza PR8 WIV and peptide antigens were formulated in 
PBS pH 7.2 at various concentrations (concentration of WIV is 
total protein content). Where mentioned, 50  µg of CpG ODN 
1826 (Invivogen) or 50% (v/v) IFA (Sigma-Aldrich) were added 
to the formulation.
Determination of association Between 
Peptides and WiV
The association of peptides to WIV particles was studied by quan-
tification of unassociated peptide in a mixture of peptides and 
WIV. Peptides were mixed with WIV in similar concentrations as 
used in the animal studies. WIV particles were subsequently spun 
down by ultracentrifugation for 2 h at 30,000 × g. Supernatant 
was collected and analyzed for peptides by mass spectrometry on 
a nanoscale LC-MS system, essentially as described by Meiring 
et  al. (15), comprising a 100- and 50-µm internal diameter in 
house-packed Reprosil-Pur C18-AQ trapping and analytical 
column, respectively. Peptides were trapped in 100% of solvent 
A (water + 5% dimethylsufoxide + 0.1% formic acid) for 10 min. 
The linear gradient for the separation ranged from 15 to 90% 
of solvent B (acetonitrile +  5% DMSO +  0.1% FA) in 25 min 
at a flow rate of 125 nL/min. The column effluent was directly 
electro-sprayed into the MS using a gold-coated fused silica-
tapered tip of 3.5  µm internal diameter. High-resolution MS1 
data were acquired on an LTQ-Orbitrap XL mass spectrometer 
(Thermo Scientific, San Jose, CA, USA) at a resolution of 60,000 
FWHM. Peptide identity was confirmed by their CID MS/MS 
fragmentation spectra, acquired on-the-fly in the LTQ mass 
analyzer on the singly or doubly charged ions of the targeted 
peptides only. The percentage of unassociated peptide was cal-
culated by comparing peptide content in supernatants of peptide 
mixed with WIV to peptide content in supernatants collected 
from solutions without WIV.
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hemolysis assay
Virosome fusion activity was determined by using a hemolysis 
assay as described previously (16). Formulations were mixed 
with human blood erythrocytes and 0.1  M 2-(N-morpholino)
ethanesulfonic acid (MES) buffer with pH ranging from 4.5 to 
5.5, and incubated at 37°C for 30 min. The released hemoglobin 
was quantified in the supernatant after centrifugation by read-
ing absorbance at 540 nm using a Synergy Mx reader (Biotek). 
Hemoglobin release from erythrocytes mixed with water was set 
as maximal hemolysis (100%).
animal studies
Animal studies were conducted according to the guidelines 
provided by the Dutch Animal Protection Act and were 
approved by the Committee for Animal Experimentation 
(DEC) of the PD-Alt campus (Bilthoven, The Netherlands) 
under protocol number PO201400134. Eight- to ten-week-
old female transgenic C57BL/6-Tg(HLA-A2.1)1Enge/J mice 
(Jackson Laboratory, maintained in-house) were used in all 
studies.
In the proof-of-principle study, mice (three per group) received 
immunizations subcutaneously (s.c.) in alternating flanks at days 
0 and 21, containing either PBS, 50 µg WIV, 1 nmol GIL peptide 
adjuvanted with 50 µg WIV or 100 nmol GIL adjuvanted with 
50 µg CpG in a volume of 100 µL.
For the dose-finding study, formulations consisting of various 
doses of WIV and GIL peptide were administered s.c. in alternat-
ing flanks of mice (six per group) at days 0 and 21.
To study the effect of adjuvant co-localization, mice (six per 
group) were immunized at days 0 and 21 either s.c. in one flank 
with PBS or 100 nmol GIL peptide adjuvanted with 25 µg WIV, 
or s.c. in separate flanks with 100 nmol GIL peptide in one flank 
and 25 µg WIV adjuvant in the opposite flank.
The effect of membrane fusion activity was assessed by immu-
nizing mice (six per group) s.c. in alternating flanks at days 0 and 
21 with 100 nmol GIL peptide adjuvanted with either 25 µg of 
fusion-active WIV or fusion-inactive WIV.
The adjuvant effect of WIV on a mix of multiple peptides was 
assessed with either a WT peptide pool (GIL, FMY, and NML; 
100  nmol each) or a modified peptide pool (G1, F5, and N53; 
100 nmol each). Mice (six per group) received an s.c. immuni-
zation in the flank at days 0 and 21 containing either PBS, WT 
peptide pool adjuvanted with 5 µg WIV or IFA, CPL peptide pool 
adjuvanted with 5 µg WIV or IFA, or only 5 µg WIV. In all studies, 
animals were sacrificed at day 35.
intracellular staining and Flow cytometry
T  cell populations were analyzed by flow cytometry. In short, 
single-cell suspensions of splenocytes were plated at a concen-
tration of 2×106 cells in a 48-well plate in RPMI medium (Life 
Technologies) with 10% Hyclone fetal calf serum (FCS, Thermo 
Scientific), and stimulated overnight with either medium, 50 ng 
peptide or 50 ng PR8 WIV. Cytokine transport was blocked by 
incubating with Golgi-plug (BD Biosciences) for the last 4  h. 
Cells were stained with anti-mouse CD8-FITC (BD Biosciences), 
anti-mouse CD4-PE (BD Biosciences), and Live-dead-Aqua 
(Invitrogen), fixated with fixation/permeabilization buffer (BD 
Biosciences), and washed with permeabilization wash buffer 
(BD Biosciences). Finally, cells were stained intracellularly with 
anti-mouse IFN-γ-APC (BD Biosciences), and IFN-γ+ CD8+ 
T  cells were quantified on a FACS Canto II flow cytometer 
(BD Biosciences). Acquired data were analyzed with FlowJo 
version 10 for Mac OSX (TreeStar Inc.). Gating strategy for the 
quantification of CD8+ IFN-γ+ T cells is shown in Figure S2 in 
Supplementary Material.
enzyme-linked immunosorbent  
spot assay (elispot)
Peptide-specific, IFN-γ-producing T  cells were determined in 
splenocytes by an IFN-γ ELISpot. 96-wells Multiscreen PVDF 
filter plates (Millipore) were activated by adding 25  µL 70% 
ethanol for 2  min and washed three times with PBS. Plates 
were coated overnight with anti-mouse IFN-γ antibodies 
(U-Cytech) at 4°C, washed three times, and blocked with 5% 
FCS (Hyclone, Thermo Scientific) in RPMI medium for 1 h at 
37°C. Subsequently, 4×105 isolated splenocytes resuspended in 
RPMI medium, 5% FCS was added to each well with or without 
100 ng of relevant peptide, and incubated overnight at 37°C, 5% 
CO2. Next, filter plates were washed five times and IFN-γ was 
detected using biotinylated anti-mouse antibodies (U-Cytech) 
and 100  µL BCIP/NBT reagent (Thermo Scientific) per well. 
Plates were washed with tap water and dried. Spots were counted 
using an A.EL.VIS ELISpot reader (Aelvis). The number of 
IFN-γ-producing cells in antigen-stimulated splenocytes was 
counted and corrected for background by subtracting the number 
of spots produced by splenocytes incubated with medium only.
statistics
Results were statistically analyzed with a one-way ANOVA 
followed by a Tukey post test for multiple comparisons. All 
statistical analyzes were performed using GraphPad Prism 6.04 
for Windows (GraphPad Software Inc.).
resUlTs
addition of WiV to gil Peptide 
enhances gil-specific T cell 
responses
As shown previously, 100 nmol GIL peptide, without adjuvant, 
was unable to induce detectable GIL-specific T cell responses 
in HLA-A2.1 transgenic mice (14). The addition of the adju-
vant CpG, a TLR9 agonist, was also insufficient to induce 
GIL-specific CD8+ T cells (Figure 1). By contrast, the addition 
of WIV to the GIL peptide resulted in the induction of high 
levels of GIL-specific CD8+ T cell responses. Importantly, WIV 
alone was able to induce low levels of GIL-specific CD8+ T cells, 
which is caused by processing of the GIL epitope present in 
the internal M1 protein of WIV. The combination of GIL and 
WIV, however, induced high levels of GIL-specific T  cells as 
compared to WIV only.
FigUre 2 | Induction of GIL-specific T cell responses by different concentrations of GIL and whole-inactivated influenza virus (WIV). HLA-A2.1 transgenic mice were 
vaccinated twice, 3 weeks apart with indicated amounts of GIL peptide and WIV. (a) Splenocytes were re-stimulated with GIL peptide and stained for intracellular 
cytokine IFN-γ. The percentages for IFN-γ+ CD8+ T cells acquired by FACS are plotted. (B) Splenocytes of immunized mice were re-stimulated with GIL peptide.  
The number of CD8+ IFN-γ-secreting cells was subsequently determined with ELISpot. (a,B) Data are shown as mean ± SD of three mice per group, each dot  
is a single replicate and data are from a single experiment. *p < 0.05, **p < 0.01 (one-way ANOVA).
FigUre 1 | Comparison of CD8+ T cell responses induced by 1 nmol GIL peptide adjuvanted with either 50 µg CpG or 50 µg whole-inactivated influenza virus 
(WIV). HLA-A2.1 transgenic mice were injected twice, 3 weeks apart with PBS (negative control), WIV or GIL peptide with indicated adjuvant. Shown are the 
responses 2 weeks after the final immunization. (a) Splenocytes were re-stimulated with GIL peptide and stained for intracellular cytokine IFN-γ. The percentages  
for IFN-γ+ CD8+ T cells acquired by FACS are plotted. Data are shown as mean ± SD of three mice per group, each circle is a single replicate and data are from a 
single experiment representative of two individual experiments. **p < 0.01, ***p < 0.001 (one-way ANOVA). (B) Representative FACS plot displaying GIL-specificity 
of IFN-γ+ CD8+ T cells in splenocytes from mice immunized with GIL peptide formulated with WIV and re-stimulated with GIL peptide.
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Both gil and WiV contribute  
to the induction of gil-specific  
T cell responses
To investigate the relative contributions of WIV on the induc-
tion of GIL-specific T cell responses, different combinations of 
amounts of peptide and WIV were tested in a mouse model by 
determining IFN-γ responses with FACS and ELISpot analyses. 
The peptide antigen dose ranged from 1 to 100  nmol, and the 
WIV dose ranged from 1 to 25 µg.
A combination of 1 nmol GIL peptide and 1 µg WIV indu ced 
very low responses (Figures 2A,B). Increasing the GIL dose to 
100  nmol led to a significant induction of GIL-specific CD8+ 
T cells. This effect was also observed when the peptide dose was 
increased from 1 to 100 nmol combined with a dose of 25 µg WIV. 
The increase of WIV from 1 to 25 µg also had a marked effect 
on the induction T cells, both with 1 and 100 nmol GIL. These 
data show that GIL and WIV induce the highest T cell responses 
when combined, whereas GIL or WIV alone induce considerably 
less T cells. It should be noted that it is estimated that 25 µg WIV 
contains approximately 535  pmol of GIL peptide; a negligible 
amount compared to the 1–100 nmol GIL peptide. These findings 
imply that the addition of WIV provides a synergistic, adjuvant-
like effect for the GIL peptide.
co-localization of gil and WiV is 
necessary to Obtain the adjuvant  
effect of WiV
The previous results show that, aside from providing additional 
GIL-epitopes, WIV acts as an adjuvant when combined with 
GIL. Next, the influence of co-localization of GIL (100  nmol) 
and WIV (25  µg) was investigated. When GIL and WIV were 
injected separately at two different sites (Figure 3A), only mod-
erate GIL-specific T  cell responses were obtained. By contrast, 
when injected at the same site, a significant induction of T cell 
responses was observed (Figures 3B,C), proving that the T cell 
response is not simply a sum of the amount of GIL present in 
the formulations. Thus, co-localization is necessary to obtain the 
adjuvant effect of WIV for the GIL peptide.
TaBle 1 | Association between GIL peptide and whole-inactivated influenza 
virus (WIV).
gil peptide (μg) WiV (μg) Unassociated gil peptide (%)
1 1 112 ± 10
100 1 111 ± 6
50 13 96 ± 5
1 25 77 ± 8
100 25 92 ± 20
1 50 87 ± 9
Indicated amounts of GIL peptide and WIV were mixed and subsequently separated 
by ultracentrifugation. The residual, unassociated peptide in the supernatant was 
quantified by using mass spectrometry. Data are shown as mean ± SD from three 
individual experiments.
FigUre 3 | Influence of co-localization on the immunogenicity of GIL 
(100 nmol) and whole-inactivated influenza virus (WIV, 25 µg). (a) HLA-A2.1 
transgenic mice were vaccinated twice, 3 weeks apart with GIL peptide and 
WIV either combined in one single flank (mixed) or separate in opposite flanks 
(separate). (B) Splenocytes were re-stimulated with GIL peptide and stained 
for intracellular cytokine IFN-γ. The percentages for IFN-γ+ CD8+ T cells 
acquired by FACS are plotted. (c) Splenocytes were re-stimulated with GIL 
peptide. The number of IFN-γ-secreting cells was subsequently determined 
with ELISpot. (a,B) Data are shown as mean ± SD of six mice per group, 
each dot is a single replicate and data are from a single experiment. 
**p < 0.01, ***p < 0.001 (one-way ANOVA).
FigUre 4 | Effect of membrane fusion activity on whole-inactivated influenza 
virus (WIV) adjuvant activity. (a) WIV was fusion-inactivated by brief exposure 
to a buffer with pH 4.5 at 37°C. Hemolysis was performed by mixing either 
WIV (“active” WIV) or fusion-inactivated WIV (“inactive” WIV) with human 
blood erythrocytes at various pHs. Fusion-mediated hemoglobin release was 
subsequently determined by spectrophotometric analysis. Data are shown as 
mean ± SD of three individual experiments. (B) HLA-A2.1 transgenic mice 
were vaccinated twice, 3 weeks apart with GIL peptide (100 µg) and either 
fusion-active or fusion-inactive WIV (25 µg). Splenocytes were re-stimulated 
with GIL peptide and stained for intracellular cytokine IFN-γ. The percentages 
for IFN-γ+ CD8+ T cells acquired by FACS are plotted. (c) Splenocytes were 
re-stimulated with GIL peptide. The number of IFN-γ-secreting cells was 
subsequently determined with ELISpot. (B,c) Data are shown as mean ± SD 
of six mice per group, each dot is a single replicate and data are from a 
single experiment. n.s. = not significant (one-way ANOVA).
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The adjuvant effect of WiV is not caused 
by Physical gil Peptide–WiV interaction
For some adjuvants, direct physical association (such as adsorp-
tion) between adjuvant and antigen is required for optimal 
antigen delivery to APCs (14, 17). The adjuvant effect observed 
by WIV might also rely on physical association between 
WIV and GIL peptide, since co-localization was shown to be 
required. The association between GIL and WIV was, therefore, 
determined by using mass spectrometry after separation of 
non-associated peptide from WIV by centrifugation (Table 1). 
Overall, little to no association was found between GIL peptide 
and WIV at various concentrations. Some association was 
observed with higher concentrations of WIV (25–50 µg), but 
not at 1  µg WIV. However, no direct correlation can be seen 
between peptide–WIV association and the immunogenicity 
of the mixtures, indicating that physical interaction between 
GIL and WIV is not the predominant mechanism behind the 
adjuvant activity of WIV.
Membrane Fusion activity is not  
required for WiV adjuvant activity
Budimir et  al. have shown that the membrane fusion activity 
of WIV was necessary for the induction of cross-reactive T cell 
responses by WIV (18). Therefore, we investigated the influence 
of the membrane fusion activity of WIV on the immunogenicity 
of the GIL and WIV combination. WIV was fusion inactivated 
by exposure to acidic pH, and loss of membrane fusion activity 
was confirmed by a hemolysis assay (Figure 4A). A mixture of 
GIL peptide and fusion-inactivated WIV was able to induce 
FigUre 5 | T cell responses against wild-type and modified peptides 
adjuvanted with whole-inactivated influenza virus (WIV). HLA-A2.1 transgenic 
mice were vaccinated twice, 3 weeks apart with peptide pools containing 
either wild-type (WT) peptides (GIL, FMY, and NML, 100 nmol each) or 
modified (mod.) peptides (G1, F5, and N53, 100 nmol each) adjuvanted  
with either WIV or 50% (v/v) incomplete Freund’s adjuvant (IFA).  
(a) Splenocytes of immunized mice were re-stimulated with either GIL  
or G1 peptide. (B) Splenocytes were re-stimulated with either FMY or F5 
peptide. (c) Splenocytes were re-stimulated with either NML or N53 peptide. 
(a–c) The number of IFN-γ-secreting cells was subsequently determined 
with ELISpot. Data are shown as mean ± SD of six mice per group, each  
dot is a single replicate and data are from a single experiment. *p < 0.05, 
**p < 0.01, ***p < 0.001 (one-way ANOVA).
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peptide-specific T  cell responses similar to those induced by 
GIL peptide with fusion-active WIV (Figures 4B,C), indicating 
that fusion activity is not critical for the adjuvant activity of 
WIV.
WiV can act as an adjuvant for Multiple 
combined Peptides
To increase the efficacy and broadness of the peptide-induced 
immune response, multiple conserved epitopes should be 
included into a peptide-based influenza vaccine. To investigate 
whether WIV also acts as an adjuvant for other peptides, two 
subdominant conserved human HLA-A2.1-restricted influenza 
epitopes, FMYSDFHFI (FMY, PA46–54) and NMLSTVLGV 
(NML, PB1413–421), were added to the mixture of GIL and WIV. 
Another method to improve the immunogenicity of peptide 
antigens is by increasing the binding affinity to MHC I through 
chemical modification (11, 19). To examine whether this in com-
bination with the improved immunogenicity of WIV adjuvant 
would further boost the immune response, chemically altered 
variants of the GIL, FMY, and NML peptide ligands, being 
[am-phg]ILGFVFTL (G1), [4-FPHE]MYSDFHF[2-AOC] (F5), 
and N[NLE]LSTVLGV (N53), were combined with WIV. As a 
reference control, peptides were also adjuvanted with the water-
in-oil-based IFA.
As described above, the GIL peptide in the peptide pool was 
able to induce GIL-specific T  cell responses when mixed with 
WIV (Figure  5A), while IFA-adjuvanted GIL peptide induced 
significantly lower T  cell responses. The modified G1 peptide 
was able to induce some GIL-specific responses, regardless of 
adjuvant; however, these responses were not statistically higher 
than the negative control group. The G1 peptide adjuvanted 
with either WIV or IFA did induce a G1-specific T cell response, 
indicating that while the modified peptide was immunogenic in 
combination with an adjuvant, it failed to induce high responses 
that were cross-reactive with the wild-type (WT) analog.
The WT FMY peptide was able to induce FMY-specific T cell 
responses in combination with either WIV or IFA (Figure 5B). 
Interestingly, the modified F5 peptide was able to induce signifi-
cantly higher FMY-specific responses compared to the WT FMY 
peptide when adjuvanted with WIV. F5 peptide adjuvanted with 
IFA did not show such an increase, indicating that WIV is a more 
potent adjuvant than IFA for the F5 peptide. This difference was 
also observed for the F5-specific responses; F5 peptide induced 
significantly higher F5-specific T cell responses when adjuvanted 
with WIV than with IFA.
Finally, the NML peptide and the modified N53 were unable 
to induce any significant T cell responses, regardless of adjuvant 
(Figure 5C). IFA-adjuvanted peptides showed incidental T cell 
responses in some animals, but these did not significantly differ 
from the WIV groups.
The individual peptides in both WT and modified pools did 
not show significant association with the WIV particles, similar 
to the previous observations with the GIL peptide alone (Table 
S1 in Supplementary Material). Thus, it is unlikely that differ-
ences in induced immune responses by the peptide vaccines 
were caused by differences in association between peptide and 
WIV.
In conclusion, two distinct effects were observed. First, we 
observed that WIV has an adjuvating effect on several peptides, 
including GIL, G1, FMY, and F5, indicating that WIV can also 
have an immunostimulating effect when combined with peptides 
other than GIL. Second, these data show that the F5 peptide was 
able to induce T cells which are cross-reactive with their wild-type 
analogs, which was also found in a previous study by Rosendahl 
Huber et al. (11).
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DiscUssiOn
Short peptides covering conserved internal influenza T  cell 
epitopes can induce cross-reactive T  cell responses. However, 
the peptides themselves are not immunogenic enough to elicit 
strong T cell responses. In recent years, multiple adjuvants have 
been utilized to improve the immunogenicity of such peptides, 
including Pam2Cys and CpG-ODN (20, 21), delivery systems, 
such as liposomes and virosomes (22, 23) and combinations 
thereof (14, 24). However, such combinations often require 
complex multi-step formulation procedures, which are difficult 
to produce on a large scale. In addition, antigen encapsulation 
and/or adsorption is sometimes very low, hampering large-scale 
production of such formulations. Furthermore, some of the 
adjuvants have not received an approval for human use, which 
hinders the evaluation of such vaccine formulations in human 
trials.
In this study, we improved the immunogenicity of influenza 
T cell epitopes by simply adding WIV to the peptides. We showed 
that the combination of WIV and GIL peptide induced signi-
ficantly higher T cell responses than the individual components. 
By screening various concentrations of GIL and WIV, we found 
that both GIL and WIV synergistically contributed to the GIL-
specific T cell response. This confirms earlier findings that WIV 
alone is able to induce influenza-specific T  cell responses in 
mice (25, 26).
While these results showed that peptide and WIV together 
elicit strong T  cell responses, the exact mode of action of 
the observed adjuvant effect of WIV is still unclear. Similar 
particulate delivery systems, such as virosomes, facilitate the 
escape of peptide antigens from the endosomal compartment 
into the cytosol, enabling processing of the peptide in the 
MHC-I pathway (14). This endosomal escape is mediated by 
the membrane fusion capabilities of influenza surface proteins. 
We showed, however, that endosomal escape due to membrane 
fusion of the WIV particle is most likely not the mechanism of 
action, since inactivation of the membrane fusion capabilities 
of WIV had no effect on its adjuvant activity. In addition, we 
showed a lack of physical association between WIV and pep-
tide, which indicates that it is unlikely that WIV functions as 
a particulate carrier system. This may be confirmed in a future 
study by conjugating the peptide with WIV and determine the 
immunogenicity of this construct. It is possible that the GIL 
peptides are cross-presented by the dendritic cells (DCs) via the 
vacuolar pathway, which does not require endosomal escape of 
the antigen, but does require the DCs to display a mature and 
activated phenotype. To acquire this mature phenotype, interac-
tion with PAMPs by pattern recognition receptors such as TLRs 
on the DC is critical. It is thus most likely that the presence of 
viral ssRNA in WIV provides strong TLR7 signaling (8), which 
activates the DCs and enables subsequent induction of T cell 
responses. Indeed, co-localization of the WIV particles with 
the peptide antigen was necessary to increase T cell responses; 
without WIV, T  cell responses were low. This supports the 
hypothesis that local maturation of DCs through TLR7 activa-
tion might be required for efficient cross presentation of the 
peptide antigen and subsequent T  cell induction. Stoel et  al. 
confirmed that immature murine DCs matured after exposure 
to WIV; CD40, CD80, and CD86 surface expression increased 
significantly after 24  h (27). Tapia-Calle et  al. found similar 
surface expression patterns in human DCs, and additionally 
showed that IRF7, STAT1, and MyD88, which all play a role 
in the TLR7 signaling pathway, were significantly increased in 
DCs upon stimulation with WIV (28).
Another contributing factor for the adjuvant effect of WIV 
might be related to an increased infiltration of inflammatory 
cells at the site of injection. Particulates such as WIV can activate 
innate cells, which is accompanied by the release of chemokines 
and cytokines (29). Particulate adjuvants can also activate NALP3 
inflammasomes, which might enhance innate and cellular immu-
nity (30). Inflammasomes are also known to be activated upon 
influenza virus infection (31). Whether the TLR7 pathway or the 
inflammasome pathway contributes to the adjuvanticity of WIV 
could be investigated in a future study using TLR7−/− and ASC−/− 
knockout mice, respectively.
In addition, WIV contains multiple other T  cell antigens, 
which may induce CD4+ T helper cells, that in turn can aid CD8+ 
CTL priming (32). In addition to studies with the GIL peptide, 
we combined WIV with a mixture of dominant and subdominant 
epitopes, either in wild-type or CPL form. CPLs were selected 
based on their improved binding affinity on MHC-I molecules 
(19), which generally enhances immunogenicity (11). WIV was 
able to improve the homologous T cell responses of both GIL and 
G1 peptides. However, the modified G1 peptide did not induce 
higher T  cell responses against the wild-type GIL epitope. By 
contrast, the modified F5 peptide was able to induce significantly 
higher FMY-specific T  cell responses compared to WT FMY 
peptide in the presence of WIV. T cell responses against NML or 
N53 were almost not detectable; it is likely that the subdominant 
nature of the peptide was the cause of this. For the peptides GIL 
and F5, WIV might be able to replace IFA, which is commonly 
used as an adjuvant for peptide antigens.
The peptides used in this study are all HLA-A2.1 binding 
peptides, which is one of the most frequently occurring alleles 
in the Caucasian population. However, allele frequencies differ 
between ethnicities, and thus multiple peptide covering multiple 
alleles should be combined to ensure complete coverage in the 
human population. Such approaches using peptide pools have 
already reached phase IIb clinical studies (33–36), with positive 
results. These T cell-inducing influenza vaccines would be ideal to 
reduce the morbidity and mortality in vulnerable people exposed 
to highly pathogenic influenza strains in the event of a pandemic, 
when a strain-specific vaccine is not yet available.
A few comparable studies with HLA-A2.1 influenza peptides 
have been conducted previously in the literature. Recently, 
Herrera-Rodriguez et  al. showed that a peptide pool consist-
ing of four modified peptides adjuvanted with ISA-51 induced 
potent T cell responses in mice (37). These T cell responses were 
able to reduce weight loss and mortality in H1N1pdm-infected 
HLA-A2.1 transgenic mice. Our group previously showed that 
a single T cell peptide delivered by CpG-adjuvanted virosomes 
was also able to reduce weight loss in H3N2-infected HLA-A2.1 
transgenic mice (14). Both these studies showed that vaccinated 
mice had approximately 200 IFN-γ-producing spot-forming 
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units (SFU)/106 cells, whereas our current study shows that mice 
vaccinated with (modified) peptides adjuvanted with WIV reach 
about 400–900 IFN-γ-producing SFU/106 cells. This may be an 
indication that our WIV-adjuvanted peptides also offer some 
protection to heterologous influenza infection in mice.
Our current study is the first to show the adjuvant effect of 
WIV on peptide-induced CD8+ T cell responses. Earlier it was 
shown that WIV can also boost humoral responses; Babb et al. 
showed that gamma-irradiated WIV was able to boost specific 
IgG and IgG2c responses to a gamma-irradiated SFV vaccine 
(10), but did not report any effect on T cell responses. Our data 
show that T  cell responses are also boosted by WIV. Future 
studies are required to determine the minimum amount of WIV 
required to induce this adjuvant effect, since the concentration of 
WIV used in this study are higher than the dose required for a 
standard influenza vaccination. Taken together, these data show 
that inactivated whole influenza virus is an effective adjuvant for 
CD8+ T cell peptide antigens, which is easy to formulate and has 
a long track record with regard to usage and safety.
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